SLIL Biomedical Corp.
Executive SummarySLIL Biomedical uses macrophage-based technology, combining sequential pathogenesis and synthetic chemistry, to develop therapeutics and diagnostics for diseases characterized by excessive cell proliferation. It was formed as the result of a merger between Sequential Medical Corp. and S'LIL Pharmaceuticals.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.